{
    "Trade/Device Name(s)": [
        "CellSearch\u2122 Circulating Tumor Cell Kit",
        "CellSearch\u2122M Circulating Tumor Cell Kit",
        "CellSearch\u2122 Epithelial Cell Kit",
        "CellSearch\u2122 Circulating Tumor Cell Control Kit"
    ],
    "Submitter Information": "Veridex, LLC",
    "510(k) Number": "K050245",
    "Predicate Device Reference 510(k) Number(s)": [
        "K031588"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NQI"
    ],
    "Summary Letter Date": "March 15, 2005",
    "Summary Letter Received Date": "February 3, 2005",
    "Submission Date": "January 30, 2005",
    "Regulation Number(s)": [
        "21 CFR 866.6020"
    ],
    "Regulation Name(s)": [
        "Immunomagnetic Circulating Cancer Cell Selection and Enumeration System"
    ],
    "Analyte Class(es)": [
        "cancer molecular",
        "immunology"
    ],
    "Analyte(s)": [
        "Circulating tumor cells of epithelial origin",
        "EpCAM",
        "Cytokeratin 8",
        "Cytokeratin 18",
        "Cytokeratin 19",
        "CD45"
    ],
    "Specimen Type(s)": [
        "Whole blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "CellTracks\u00ae AutoPrep System",
        "CellSpotter\u00ae Analyzer",
        "CellTracks\u00ae Analyzer II"
    ],
    "Method(s)/Technology(ies)": [
        "Immunomagnetic selection",
        "Fluorescent labeling"
    ],
    "Methodologies": [
        "Enumeration of immunomagnetically selected epithelial tumor cells"
    ],
    "Submission Type(s)": [
        "Kit",
        "Control",
        "Analyzer",
        "System"
    ],
    "Document Summary": "FDA 510(k) summary for CellSearch Circulating Tumor Cell Kit utilizing immunomagnetic selection and fluorescent labeling to enumerate epithelial-origin circulating tumor cells in whole blood for metastatic breast cancer prognosis.",
    "Indications for Use Summary": "Intended for enumeration of circulating tumor cells of epithelial origin (CD45-, EpCAM+, and cytokeratins 8, 18, and/or 19+) in whole blood; presence of \u22655 CTC/7.5 mL blood is associated with decreased progression free and overall survival in metastatic breast cancer patients.",
    "fda_folder": "Immunology"
}